Joint disease caused by defective gp130-mediated STAT signaling

Area of Science:

• Immunology
• Molecular Biology
• Rheumatology

Background:

• Interleukin-6 (IL-6) is a key cytokine regulating immune responses and inflammation.
• IL-6 signaling relies on the gp130 receptor subunit, crucial for the LIF/IL-6 cytokine family.
• Dysregulated cytokine signaling is implicated in inflammatory diseases like rheumatoid arthritis.

Purpose of the Study:

• To investigate the role of STAT-binding sites in gp130 signaling.
• To explore the consequences of impaired STAT activation on gp130-mediated signaling.
• To understand the potential link between gp130 signaling defects and joint disease.

Main Methods:

• Generation of knock-in mice (gp130DeltaSTAT/DeltaSTAT) with deleted STAT-binding sites in the gp130 gene.
• Preservation of Janus kinases (JAKs) and SHP-2 binding sites in the mutant gp130.
• Analysis of physiological and cellular responses in the mutant mice.

Main Results:

• The gp130DeltaSTAT/DeltaSTAT mice exhibited blastocyst implantation defects, gastrointestinal ulceration, and severe joint disease mimicking rheumatoid arthritis.
• Synovial cells showed hyper-responsiveness to LIF/IL-6 family cytokines.
• This hyper-responsiveness was linked to sustained SHP-2/Ras/Erk activation due to impaired SOCS-1 induction.

Conclusions:

• The disruption of the balance between STAT and SHP-2/Ras/Erk signaling pathways contributes to joint disease in the gp130DeltaSTAT/DeltaSTAT mouse model.
• These findings offer insights into the pathogenesis of rheumatoid arthritis.
• The study suggests potential therapeutic targets for rheumatoid arthritis by modulating gp130 signaling pathways.